Recruiting

PAVE System

Sponsor:

NeuroAEye LLC

Code:

NCT07185971

Conditions

Homonymous Hemianopsia

Homonymous Quadrantanopia

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display

Study Details

Brief summary:

This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual stimulation to subjects diagnosed with visual field loss.

The primary objective is to demonstrate that there is an improvement in the visual field after use of the PAVE therapy over a period of eight weeks with three sessions per week. The primary outcome is an increase in visual field area as measured with Goldmann-type kinetic perimetry.

The secondary outcome will be demonstration that the subjective assessment of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) is better after PAVE therapy when compared to before therapy.

The participants will visit the investigators office at the start of the study to establish a baseline for visual field size and visual field function. The subject will use PAVE in the office or at home three times per week for eight weeks. There will be twenty four therapy sessions in total. At four weeks the subject will visit the office and have perimetry measurements. At eight weeks the subject will visit the office and have perimetry measurements and complete the NEI-VFQ survey. Four weeks after the completion of the therapy sessions a follow up visit will take place where visual field measurement using kinetic perimetry and NEI-VFQ will be administered.

Conditions

Homonymous Hemianopsia

Homonymous Quadrantanopia

Study ID

NCT07185971

Start date

Mar 16, 2026

Status verified date

Mar, 2026

Completion date

Aug, 2026

Anticipated

Primary completion date

Jul, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset
  • The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction.

Exclusion Criteria:

  • Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy.
  • Concurrent use of another visual therapy
  • Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.)
  • Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects
  • Insufficient fixation ability
  • Use of life supporting external medical device such as infusion pumps, ventricular assist devices, etc.
  • Presence of active implantable medical device including but not limited to cardiac pacemakers, defibrillators, nerve stimulators, cochlear implants, etc.
  • Subjects with known photosensitive epilepsy.
  • Subjects with chronic active infections on the head and face should be excluded from the study
  • Patients with known immune disorders for whom an infection could be life threatening should be excluded from the study.

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Test

Treatment using actual PAVE therapy software operating on a virtual reality head mounted display three times per week for eight weeks.

Interventions

PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display

PAVE (Parallactic Visual-Field Enhancement) treatment is visual stimulation using a virtual reality head mounted display. The treatment is three times per week and entails two 7 minute sessions separated by a minimum 1 minute intermission. The actual therapy is preceded by a visual field assessment and is followed by a second visual field assessment.

Primary outcome measure

  • Population Mean Change in Visual Field Area [ Time Frame: Visual field area will be assessed at the baseline, week 4, week 8, and follow up at week 12. ]

Central Contacts and Locations

Central contacts

Paige Clinical Study Coordinator

319-366-3500paige.eyecare@gmail.com

Locations

Dr. D. M. Fitzgerald & Associates

Recruiting

Cedar Rapids, Iowa, United States, 52404

Contacts

Paige Primary Study Coordinator

319-366-3500paige.eyecare@gmail.com

Larissa Study Coordinator

Larissabisig@gmail.com

Principal Investigator:

DeAnn Fitzgerald, Doctor of Optometry

Neuro-Vision Associates of North Texas

Recruiting

Prospect, Kentucky, United States, 40059

Contacts

Principal Investigator:

Charles Shidlofsky, Doctor of Optometry

More Information

Sponsor

NeuroAEye LLC

Last update posted

Apr 2, 2026

Last verified

Mar, 2026

Keywords

  • PAVE
  • Parallactic Visual-Field Enhancement
  • NeuroAEye
  • chronic visual field loss

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by NeuroAEye LLC on 2026-04-02.